Inclusion Criteria:  Suspected or confirmed malignancy Planned comprehensive genomic (> 100 genes) and/or molecular analysis; or genomic and/or molecular data available from prior sequencing Baseline demographics and treatment information available Willingness for future contact by BIRG study personnel to provide information regarding associated cancer outcomes and treatment. Signed informed consent to participate in the study. Living in the United States at the time of enrollment  Exclusion Criteria:  Life expectancy < 3 months